Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for treating cancer using a combination of chk1 and atr inhibitors

a technology of atr inhibitor and chk1 is applied in the field of cancer treatment using a combination of atr inhibitor and chk1 to achieve the effect of surprising the synergistic effect of treatmen

Pending Publication Date: 2022-08-11
VERTEX PHARMA INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention describes a new method for treating cancer by combining two compounds that target different protein kinases. This combination works better than either compound alone in treating cancer, and it can be used in conjunction with DNA damaging agents. The technical effect of this invention is the synergistic effect of combining two compounds that target the same biological pathway, which is helpful in treating cancer.

Problems solved by technology

Failure to repair replication stress can lead to lethal double strand breaks or deleterious DNA mutation.
This is attributed to activation of compensatory DNA repair signaling in normal cells, which is often not available to cancer cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating cancer using a combination of chk1 and atr inhibitors
  • Method for treating cancer using a combination of chk1 and atr inhibitors
  • Method for treating cancer using a combination of chk1 and atr inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

n of Chk1 and ATR Inhibition Leads to High Levels of DNA Damage

[0292]As shown in FIG. 1, the impact of Chk1 inhibition by AZD7762 on DNA damage levels from treatment of cancer cells with the ATR inhibitor VE-821 was assessed by measuring the accumulation of pan nuclear γH2AX, a widely used marker of DNA damage. γH2AX was detected by western blot. U2OS cancer cells were incubated overnight in 96 well plates and treated for 8hr. with DMSO AZD7762 (60 nM) and / or VE-821 (10 uM). Cells were stained with anti phosphor (serin 139) histone H2AX antibody as primary and Alexa 555 as secondary. Operetta was used to take images, which were analyzed using Columbus software. Intensity ≥2000 AU was consider as pan nuclear γH2AX cell positive. Data are presented as mean±S.E.M.

[0293]Treatment of U2OS cancer cells with either the ATR inhibitor VE-821 or the Chk1 inhibitor AZD7762 alone had minimal impact on the percentage of cells positive for pan nuclear γH2AX (20% cells staining positive for pan nu...

example 2a

of Chk1 or Expression of Inactive Mutant Forms of Chk1 Sensitise Cancer Cells to ATR Inhibition

[0294]Referring to FIG. 2A and FIG. 2B, the impact of Chk1 inhibition or expression of inactive Chk1 mutant on cell response to the ATR inhibitor VE-821 was assessed using a clonogenic survival assay in a variety of cancer cells. 500 cells of U2OS, MCF-7, DLD-1, DLD-1 Chk-1S317A / −, DLD-1 Chk-1+ / −, DLD-1 ATRS / S and 1000 cells of VH-10 were plated on 10 cm plate. After 5 hr. of incubation (5% CO2 at 37° C.) vehicle (0.05% DMSO max) various concentration of ATR inhibitor VE-821 were directly added to the media containing plate and incubated for 72 hr. At the end of 72 hr. of incubation, vehicle and drug containing media was replaced with fresh media and further incubated for another 5-8 days before plates were fixed and stained with 4% methylene blue in MeOH and colonies were counted manually. Each data point represents a triplicate data set±SEM.

[0295]Inhibition of Chk1 by AZD7762 (20 nM) res...

example 2b

of the cMYC Oncogene Sensitizes cells to the Combination of ATR and Chk1 inhibition

[0296]Referring to FIG. 2C, an isogenic cell line pair differing only in the expression of the oncogene cMYC (HA1EB-GFP parental and cMYC transformed cells, HA1EB-GFP-cMYC) were treated with either VE-821 alone (at concentrations up to 5 μM), AZD7762 alone (30 nM) or the combination of VE-821 and AZD7762 for 72 hours. Cell viabilty was assessed by resazurin staining. Neither VE-821 nor AZD7762 had a marked effect on viability of the parental cells. Additionally, AZD7762 alone did not impact the viability of the cMYC transformed cells. In contrast, VE-821 reduced the viability of cMYC transformed cells (˜40% viable cells remaining) and the combination markedly reduced cell viability of the cMYC transformed cells (<5% viable cells remaining).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to methods of treating cancer in a patient by administering a compound useful as an inhibitor of ATR protein kinase in combination with a compound useful as an inhibitor of Chk1 protein kinase. The aforementioned combination displays a surprising synergistic effect in treating cancer despite the targeted protein kinases being within the same biological pathway. Moreover, the present invention also relates to methods of treating cancer by administering a compound useful as an inhibitor of ATR protein kinase; administering a compound useful as an inhibitor of Chk1 protein kinase; as well as administering a DNA damaging agent to a patient.The compounds utilized in this invention are represented by formula I and formula II:wherein the variables are as defined herein.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application claims the benefit under 35 U.S.C. § 119 of U.S. Provisional Application No. 62 / 013,136, filed Jun. 17, 2014; U.S. Provisional Application No. 62 / 043,530, filed Aug. 29, 2014; U.S. Provisional Application No. 62 / 073,082, filed Oct. 31, 2014; and U.S. Provisional Application No. 62 / 161,438, filed May 14, 2015.BACKGROUND OF THE INVENTION[0002]ATR (“ATM and Rad3 related”) is a key mediator of cellular responses to a DNA damage structure that is characterized by tracts of single stranded DNA coated by replication protein A (RPA). RPA coated single stranded DNA commonly arises as a result of replication stress, which occurs when a cell attempts to replicate DNA through unresolved DNA damage lesions. Failure to repair replication stress can lead to lethal double strand breaks or deleterious DNA mutation. ATR along with its substrates coordinates multiple cell functions in response to replication stress including cell cyc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/519A61K45/06A61K31/497A61K31/4535A61K31/5377A61K31/4709A61K31/551A61N5/10A61K31/4985A61K31/4965
CPCA61K31/519A61K45/06A61K31/497A61K31/4535A61K31/4965A61K31/4709A61K31/551A61N5/10A61K31/4985A61K31/5377A61P35/00A61P43/00A61K2300/00A61K45/00
Inventor HELLEDAY, THOMASSANJIV, KUMAR
Owner VERTEX PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com